Jpmorgan Chase & CO Ocular Therapeutix, Inc Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Ocular Therapeutix, Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 84,645 shares of OCUL stock, worth $666,156. This represents 0.0% of its overall portfolio holdings.
Number of Shares
84,645
Previous 85,373
0.85%
Holding current value
$666,156
Previous $583,000
26.24%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding OCUL
# of Institutions
172Shares Held
136MCall Options Held
150KPut Options Held
225K-
Summer Road LLC West Palm Beach, FL14.4MShares$113 Million98.8% of portfolio
-
Vr Adviser, LLC New York, NY12.8MShares$100 Million11.5% of portfolio
-
Deep Track Capital, LP Greenwich, CT12.7MShares$100 Million4.08% of portfolio
-
Black Rock Inc. New York, NY11.5MShares$90.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.38MShares$66 Million0.0% of portfolio
About OCULAR THERAPEUTIX, INC
- Ticker OCUL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,966,896
- Market Cap $606M
- Description
- Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...